Asarfi HospitalBOM:543943 -4.82%65 EBITDA Margin % is 18.48% as of Mar. 2026, which is 10% below its 10-year median of 20.51. GuruFocus rates BOM:543943 with a GF Score™ of 65/100 and a GF Value™ of ₹194.15 (Fairly Valued). The stock has 6 warning signs investors should review. Among 666 Healthcare Providers & Services companies, Asarfi Hospital ranks better than 80.33% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Asarfi Hospital's EBITDA for the
three
months ended in Mar. 2026 was ₹84 Mil. Asarfi Hospital's Revenue for the
three
months ended in Mar. 2026 was ₹452 Mil. Therefore, Asarfi Hospital's EBITDA margin for the quarter that ended in Mar. 2026 was 18.48%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Asarfi Hospital EBITDA Margin % Related Terms
Asarfi Hospital EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Asarfi Hospital's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543943 vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Asarfi Hospital's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asarfi Hospital EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Asarfi Hospital's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Asarfi Hospital's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asarfi Hospital (BOM:543943) has a EBITDA Margin % of 18.48% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Asarfi Hospital and its competitors. This is 10% below median its historical median of 20.51. Over the past decade, Asarfi Hospital's EBITDA Margin % has ranged from 14.53 to 25.51. According to the industry distribution chart, Asarfi Hospital ranks #131 out of 666 companies in the Healthcare Providers & Services industry, placing it in the top 19.7%.
Is Asarfi Hospital's EBITDA Margin % too high?
Asarfi Hospital's current EBITDA Margin % of 18.48% is 10% below median its 10-year median of 20.51. Over the past 10 years, this metric has ranged from a low of 14.53 to a high of 25.51. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Asarfi Hospital's value of 18.48% is 81% above this industry median. Based on the distribution chart, Asarfi Hospital ranks #131 out of 666 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Asarfi Hospital has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Asarfi Hospital's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Asarfi Hospital ranks #131 out of 666 companies for EBITDA Margin %. This places Asarfi Hospital in the top 20% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.21. Asarfi Hospital's value of 18.48% is 81% above this benchmark. Historically, Asarfi Hospital's own EBITDA Margin % has ranged from 14.53 to 25.51 over the past decade. While the company's 10-year median is 20.51 vs. the industry median of 10.21, Asarfi Hospital has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 666 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Asarfi Hospital's current EBITDA Margin % of 18.48% is 81% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Asarfi Hospital and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Asarfi Hospital's current EBITDA Margin % is 18.48%, which is 10% below median its own 10-year median of 20.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asarfi Hospital stock overvalued right now?
Based on GuruFocus' analysis, Asarfi Hospital (BOM:543943) is currently considered Fairly Valued. The stock's GF Value™ is ₹194.15, compared to a current price of ₹214.40 — trading 10.4% above its estimated fair value. The current EBITDA Margin % is 18.48%, which is 10% below median its 10-year median of 20.51 and 81% above the Healthcare Providers & Services industry median of 10.21. Asarfi Hospital's overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Asarfi Hospital (BOM:543943), the current EBITDA Margin % is 18.48% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Asarfi Hospital (BOM:543943) Overvalued in 2026?
Based on GuruFocus' analysis, Asarfi Hospital stock appears to be overvalued.
The current stock price of ₹214.40 is trading 10.4% above its estimated GF Value™ of ₹194.15.
GuruFocus considers Asarfi Hospital to be Fairly Valued.
Key valuation signals for BOM:543943:
EBITDA Margin %: 18.48% (10% below median its 10-year median of 20.51)
GF Value™: ₹194.15 vs. price of ₹214.40 (10.4% above fair value)
Industry Position: 81% above the Healthcare Providers & Services median (#131 of 666)
No single metric tells the full story. See the BOM:543943 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Asarfi Hospital Ltd provides healthcare facilities to the people of Jharkhand. It is a multi-specialty hospital offering healthcare facilities. The company is committed to delivering valued healthcare services to patients that include prevention, treatment, and proper rehabilitation.
65GF Score
Get the complete analysis for BOM:543943
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543943 has been successfully added to your 
